GlassScriptPhysician profile
Candace M Fortune
NPI 1447360482
$1,925.77
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $384.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $423.92 | 2019-2020 | |
| Neuronetics, INC. | $357.46 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $286.68 | 2019 | |
| Lundbeck LLC | $249.73 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $221.44 | 2019 | |
| Neurocrine Biosciences, INC. | $122.53 | 2020 | |
| Shire North American Group INC | $109.41 | 2019 | |
| Adlon Therapeutics L.P. | $37.40 | 2020 | |
| Tris Pharma INC | $23.90 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.16 | 2019 | |
| Mdd US Operations, LLC | $21.33 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.46 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.76 | 2019 | |
| Bausch Health US, LLC | $14.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Candace Fortune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.